Friday, 26 Sep 2025
  • About Us
  • Contact Us
  • Terms and Conditions
  • Privacy Policy
Subscribe
Life Care News
  • Home
  • Business
    • Business Wire
    • Globenews Wire
  • News
    NewsShow More
    बिग बॉस 19 एपिसोड 32: जबरदस्त टकराव, टूटी दोस्तियां और चौंकाने वाला मोड़!
    बिग बॉस 19 एपिसोड 32: जबरदस्त टकराव, टूटी दोस्तियां और चौंकाने वाला मोड़!
    25/09/2025
    Bigg Boss 19 Episode 32: Explosive Clashes, Broken Friendships and a Shocking Twist!
    Bigg Boss 19 Episode 32: Explosive Clashes, Broken Friendships and a Shocking Twist!
    25/09/2025
    Abu Dhabi Autonomous Summit to define the future of smart mobility as part of Abu Dhabi Autonomous Week 2025
    Abu Dhabi Autonomous Summit to define the future of smart mobility as part of Abu Dhabi Autonomous Week 2025
    25/09/2025
    VESTIAIRE COLLECTIVE RELEASES FIRST MENSWEAR RESALE REPORT AS PART OF ITS MEN’S CATEGORY LAUNCH
    VESTIAIRE COLLECTIVE RELEASES FIRST MENSWEAR RESALE REPORT AS PART OF ITS MEN’S CATEGORY LAUNCH
    25/09/2025
    Bigg Boss 19 Review Explosive Fights, Shocking Nominations & Abhishek’s Captaincy | Episode Analysis
    Bigg Boss 19 Review Explosive Fights, Shocking Nominations & Abhishek’s Captaincy | Episode Analysis
    25/09/2025
  • Tech
  • Health
  • Sports
  • Entertainment
  • Automobile
  • 🔥
  • news
  • global
  • Business
  • june
  • today
  • announced
  • july
  •  and
  •  the
  • Tech
Font ResizerAa
Life Care NewsLife Care News
  • Home
  • Business
  • News
  • Tech
  • Health
  • Sports
  • Entertainment
  • Automobile
Search
  • Home
  • Business
    • Business Wire
    • Globenews Wire
  • News
  • Tech
  • Health
  • Sports
  • Entertainment
  • Automobile
Follow US
© 2022 Foxiz News Network. Ruby Design Company. All Rights Reserved.
Health

ERA Congress: Long-term data show sustained efficacy and safety of zigakibart in patients with IgA nephropathy

PRNW Agency
Last updated: 05/06/2025 7:53 AM
PRNW Agency
Share
2 Min Read
ERA Congress: Long-term data show sustained efficacy and safety of zigakibart in patients with IgA nephropathy
SHARE
ERA Congress: Long-term data show sustained efficacy and safety of zigakibart in patients with IgA nephropathy

VIENNA, June 5, 2025 /PRNewswire/ — New 100-week data from the ongoing Phase 1/2 study of zigakibart, an investigational anti-APRIL monoclonal antibody, reinforce its potential as a disease-modifying treatment for IgA nephropathy (IgAN). Findings presented today at the 62nd ERA Congress demonstrate sustained proteinuria remission, stable kidney function, and a reassuring safety profile.

- Advertisement -

IgAN is the most common form of glomerular disease worldwide and a frequent cause of chronic kidney disease. Its pathogenesis is marked by inflammation and progressive kidney damage, which can lead to kidney failure. Many patients are unaware they have the condition until significant kidney damage has occurred, and 50% of IgAN patients will ultimately develop kidney failure.

- Advertisement -

By targeting the APRIL pathway and reducing production of pathogenic galactose-debecause ofgA1), zigakibart addresses a key driver of disease progression. “Zigakibart is designed to intercept the initiating factor in IgAN pathogenesis, offering a new approach that may halt or significantly delay progression”, explained lead investigator Professor Jonathan Barratt.

The ADU-CL-19 trial included 40 adults with biopsy-confirmed IgAN and persistent proteinuria despite stable supportive therapy. Patients received zigakibart every two weeks via intravenous infusion or subcutaneous injection, in addition to maximally tolerated renin–angiotensin system inhibitors (RASi) unless RASi-intolerant – demonstrating efficacy beyond standard care.

- Advertisement -

At Week 100, proteinuria was reduced by 60% from baseline. Over half of patients (55%) reached <500 mg/24 h, and 31% achieved <300 mg/24 h, indicating deeper remission. Estimated glomerular filtration rate (eGFR) remained stable across subgroups. "The consistency of eGFR stabilisation over 100 weeks, even across proteinuria response groups, is particularly encouraging," said Prof. Barratt.

- Advertisement -

Treatment also led to sustained reductions in serum immunoglobulins, including a 74% drop in IgA and pathogenic Gd-IgA1, consistent with APRIL pathway inhibition.

Zigakibart was well tolerated throughout. Most adverse events were mild or moderate, with no treatment-related serious infections or discontinuations. Infections were the most common AEs; the study coincided with a high prevalence of COVID-19.

- Advertisement -

This is the longest duration of eGFR stabilisation reported for an anti-APRIL agent in IgAN. “These long-term results build confidence in zigakibart as a potential cornerstone therapy for IgAN,” said Prof. Barratt. “We’re excited to see how the upcoming Phase 3 trials will further define its role.”

- Advertisement -

The global Phase 3 BEYOND study is now evaluating zigakibart in a broader population, with primary proteinuria endpoints at 40 weeks and long-term kidney function through 104 weeks.

View original content:https://www.prnewswire.co.uk/news-releases/era-congress-long-term-data-show-sustained-efficacy-and-safety-of-zigakibart-in-patients-with-iga-nephropathy-302470916.html

- Advertisement -
Cytokinetics Announces Primary Results from MAPLE-HCM Presented at the European Society of Cardiology Congress 2025 and Published in The New England Journal Of Medicine
Nexalus Named a Winner of Fast Companys 2025 World Changing Ideas Awards for its Revolutionary Data Center Liquid Cooling Technology
PSYENCE GROUP INC. Announces Offering of up to C$600,000 Non-Brokered Private Placement of Common Shares
AUTOMOBILI PININFARINA UNVEILS ONE-OF-A-KIND BATTISTA NOVANTACINQUE TO CELEBRATE 95 YEARS OF ICONIC DESIGN
Abinopharm, Inc. and EGT Synbio Announce Successful Human Clinical Trials on Oral L-Ergothioneine (Dr.Ergo) for Skin Health
TAGGED:antiaprilantibodydamagedatadiseasediseasemodifyingfailurefindingsigaiganinvestigationaljunekidneyleadmonoclonalnephropathyof zigakibartongoingpathogenesispatientsphasepotentialpresentedprogressionreinforcestudytreatmentviennaweekzigakibart
Share This Article
Facebook Copy Link Print
- Advertisement -

Your Trusted Source for Accurate and Timely Updates!

Our commitment to accuracy, impartiality, and delivering breaking news as it happens has earned us the trust of a vast audience. Stay ahead with real-time updates on the latest events, trends.
FacebookLike
XFollow
PinterestPin
InstagramFollow
YoutubeSubscribe
LinkedInFollow
MediumFollow

Most Selling Products

Top Picks, Trending Now – Discover the Best Sellers!
Tecno Camon 20 Premier 5G

Tecno Camon 20 Premier 5G

Dark Welkin | 8GB RAM + 512GB Storage (Expandable RAM up to 16GB) | Industry’s 1st 50MP RGBW-Pro Camera | Segment-First 108MP Ultra-Wide Macro Lens | 6.67" 120Hz 10-bit AMOLED In-Display

iQOO Z10 Lite 5G

iQOO Z10 Lite 5G

Titanium Blue | 6GB RAM + 128GB Storage | Dimensity 6300 5G with 433K+ AnTuTu Score | Robust 6000mAh Battery | IP64 Rated + Military-Grade Shock Resistance

OnePlus 13s

OnePlus 13s

Black Velvet | 12GB RAM + 256GB Storage | Flagship Snapdragon® 8 Elite Chipset | Exceptional Battery Life in a Compact Form | Lifetime Display Warranty Included

Samsung Galaxy A55 5G

Samsung Galaxy A55 5G

Awesome Iceblue | 8GB RAM + 256GB Storage | Premium Metal Frame | 50MP OIS Main Camera with Nightography | IP67 Water & Dust Resistance | Gorilla Glass Victus+ | sAMOLED Display with Vision Booster

You Might Also Like

Neusoft Medical Systems Launches China’s First Photon-Counting CT with NMPA Approval
Tech

Neusoft Medical Systems Launches China’s First Photon-Counting CT with NMPA Approval

27/08/2025
Celldex Presents Data Demonstrating Profound Long Term Improvement in Angioedemain Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025
Health

Celldex Presents Data Demonstrating Profound Long Term Improvement in Angioedemain Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025

15/06/2025
Nokia launches Autonomous Network Fabric to help customers accelerate network automation
Tech

Nokia launches Autonomous Network Fabric to help customers accelerate network automation

18/06/2025
RAEOA and CMC Ignite a New Chapter: Oecusse to Lead Timor-Lestes Modernization
Business

RAEOA and CMC Ignite a New Chapter: Oecusse to Lead Timor-Lestes Modernization

07/07/2025
Life Care News
Facebook Twitter Youtube Rss Medium

Life Care News:


We increase the awareness of millions of users through our news networks. We are one of the most trusted news networks in the world.

Top Categories
  • Home
  • Business
  • News
  • Tech
  • Health
  • Sports
  • Entertainment
  • Automobile
Usefull Links
  • About Us
  • Contact Us
  • Terms and Conditions
  • Privacy Policy
Copyright © 2015 – 2025 LifeCareNews Network. All Rights Reserved. LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283
Life Care NewsLife Care News
Copyright © 2015 - 2025 LifeCareNews Network. All Rights Reserved. LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?